Print

Simulation study highlights the potential driving risk posed by patients with obstructive sleep apnoea

The potential driving risk posed by patients with obstructive sleep apnoea syndrome (OSAS) is highlighted in a simulation study presented today (7 September, 2016) at this year's European Respiratory Society (ERS) International Congress in London. The study is by Dr Akshay Dwarakanath and Dr Mark Elliott, St. James' University Hospital, Leeds, UK and colleagues.

Some OSAS patients are at higher risk of being involved in traffic accidents. There is significant variation in the advice given by doctors on this issue. However, in this study, standard deviation of lane position (SDLP) in a driving simulator was used to try to identify potential risk and create a model for use in future cases.

Various data were collected from patients, including their 'Epworth Sleepiness Score'(ESS) – a validated sleepiness score to assess subjective sleepiness, and also their oxygen desaturation index (ODI) – a measure of the severity of their OSAS. A total of 129 untreated OSAS patients (Mean age 53 years, ESS 14, ODI 41,Body mass index 36, years with driving licence 31) and 79 controls (mean Age 56 years, ESS 4, BMI 28, licence years 34) completed a driving questionnaire prior to simulator run. Controls performed the simulator run once while OSAS patients performed the simulator run on two occasions. Simulator outcome was based on preset criteria, with three potential results – pass, intermediate, and fail.

OSAS patients as compared to controls reported more episodes of nodding, admitted to a high chance of sleepiness while driving, and were less likely to pass (31% versus 53%) and more likely to fail (20% v/s 0%) than controls. In the controls, 53% passed, 47% were intermediate and nobody failed. In the OSAS patients, 31% passed, 49% were intermediate and 20% failed. Lane deviation was significantly worse in those who failed the test.

The authors say: "Worse lane position deviation is a marker of poor driving performance and this is significantly worse in OSAS patients who fail the simulator as compared to controls. Comparing with controls may be useful in advising patients whether they are at increased risk of an accident. Defining a normal range based on a combination of real time events, simulator performance and outcome holds promise and is a step ahead towards developing an objective test in evaluating the at risk OSAS patients."

They add that on average untreated OSAS patients are at a 2-6 times increased a risk of road traffic accidents as compared to controls. "We have also shown that nodding at the wheel and admitting to sleepiness at the wheel are more likely in patients as compared to controls," says Dr Elliott. "At the moment there are no validated tools to assess this aspect."

Since 2-4% of the general population suffers OSAS, the authors say it is vital that objective tests exist to ensure the safety of people driving and other road users. There is current advice from the Driver and Vehicle Licencing Agency (DVLA) for patients and medical professionals, but Dr Elliott says: "The current criteria are arbitrary, loosely based on evidence and have the potential to prevent a lot of people from driving who are in fact safe to drive. This has major potential implications for society and the economy. For example, OSAS is more common in the overweight and, many lorry drivers are overweight; if they are prevented from driving unnecessarily this has major implications for them and their employers. There is also the possibility that the problem will be driven underground without proper tools for assessment. There is considerable variability in the advice the clinicians give. Having an objective test would be a real advantage."

Notes to editors:

Press Office at ERS Congress in London (Saturday 3, September - Wednesday 7, September 2016):
Lauren Anderson: lauren.anderson@europeanlung.org / 07920 339040
David Sadler: 07880 451068
Beth Maguire: beth.maguire@europeanlung.org / 07884541827